Cyxtera Results Presentation Deck

Transaction Adjusted EBITDA Bridge: Q4 2021 to Q4 2022 ($ in Millions) Cyxtera $48.0 Q4'21 +$14.5 Change in Revenue -$2.2 Change in Cost of Revenue (2) -$7.3 Change in SG&A +$8.8 Change in Adjustments (1)(2) $61.8 Q4'22 (1) Includes pro forma EBITDA adjustments related to one-time stand-up costs, recurring expenses, restructuring & cost-savings initiatives, as well as product development & start-up costs (2) Excludes $153.6M Goodwill Impairment and $1.1 in restructuring, impairment, site closures and related cost inQ4'22 and excludes $22.8M of change in fair value of warrant liabilities and $1.4M in restructuring, impairment, site closures and related cost in Q4'21 13

View entire presentation